Clearside Biomedical announces plans for Phase 2b ODYSSEY trial of CLS-AX in wet AMD

Clearside Biomedical, Inc.

Phase 2b trial ODYSSEY to enroll 60 patients with wet AMD; 2:1 randomization CLS-AX vs aflibercept.
Primary outcome: mean change in BCVA from baseline to Week 36; secondary include CST and treatment burden.
CLS-AX arm: 3 aflibercept loading doses + CLS-AX at baseline, then at least every 24 weeks.
Enrollment starts Q2 2023; topline results expected in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.